Literature DB >> 17917051

Structural requirements and applications of inhibitory oligodeoxyribonucleotides.

Robert F Ashman1, Petar Lenert.   

Abstract

Synthetic oligodeoxyribonucleotides (ODN) bearing certain sequence characteristics mimic bacterial DNA by activating B cells and dendritic cells through Toll-like receptor (TLR) 9, an event that potentiates both humoral and cell-mediated immunity. ODN sharing some of the sequence characteristics of strong stimulatory (ST-) ODN, but substituting GGG for CGTT, competitively inhibit ST-ODN-driven events. An ODN with the same length and base composition as a strong ST-ODN, but lacking both ST- and IN-sequence requirements, has neither ST- nor IN-activity. Whereas, certain sequence changes strongly influence ST-ODN activity in human cells relative to mouse cells and B cells relative to non B cells, the strongest IN-ODN appear to work well in both species and multiple cell types. Converting from the natural phosphodiester backbone to a nuclease-resistant phosphorothioate backbone increases the sensitivity to ST-ODN about 2 logs and to IN-ODN 3 logs, while increasing the impact of critical base changes in ST-ODN and diminishing it in IN-ODN. Examples where IN-ODN have been used in vivo to interrupt autoimmune and other TLR-9-induced inflammatory states are described.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917051     DOI: 10.1007/s12026-007-0065-4

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  47 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 2.  Toll-like receptors in the induction of the innate immune response.

Authors:  A Aderem; R J Ulevitch
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

3.  Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation.

Authors:  Ihsan Gursel; Mayda Gursel; Hiroshi Yamada; Ken J Ishii; Fumihiko Takeshita; Dennis M Klinman
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

4.  Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides.

Authors:  Rainald A Zeuner; Ken J Ishii; Martin J Lizak; Ihsan Gursel; Hiroshi Yamada; Dennis M Klinman; Daniela Verthelyi
Journal:  Arthritis Rheum       Date:  2002-08

5.  Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.

Authors:  Jungwoo Choe; Matthew S Kelker; Ian A Wilson
Journal:  Science       Date:  2005-06-16       Impact factor: 47.728

6.  Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs.

Authors:  D Verthelyi; K J Ishii; M Gursel; F Takeshita; D M Klinman
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

7.  Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis.

Authors:  G M Deng; I M Nilsson; M Verdrengh; L V Collins; A Tarkowski
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

8.  Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.

Authors:  Parviz Ahmad-Nejad; Hans Häcker; Mark Rutz; Stefan Bauer; Ramunas M Vabulas; Hermann Wagner
Journal:  Eur J Immunol       Date:  2002-07       Impact factor: 5.532

9.  Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.

Authors:  Mark Rutz; Jochen Metzger; Tanja Gellert; Peter Luppa; Grayson B Lipford; Hermann Wagner; Stefan Bauer
Journal:  Eur J Immunol       Date:  2004-09       Impact factor: 5.532

10.  Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation.

Authors:  Ken J Ishii; Fumihiko Takeshita; Ihsan Gursel; Mayda Gursel; Jacqueline Conover; Andre Nussenzweig; Dennis M Klinman
Journal:  J Exp Med       Date:  2002-07-15       Impact factor: 14.307

View more
  9 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

Review 2.  Immunology at the University of Iowa.

Authors:  Gail A Bishop
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Aggregation and secondary loop structure of oligonucleotides do not determine their ability to inhibit TLR9.

Authors:  Robert F Ashman; J Adam Goeken; Petar S Lenert
Journal:  Int Immunopharmacol       Date:  2011-03-02       Impact factor: 4.932

4.  IFN-α production by human mononuclear cells infected with varicella-zoster virus through TLR9-dependent and -independent pathways.

Authors:  Hong-Ren Yu; Hsin-Chun Huang; Ho-Chang Kuo; Jiunn-Ming Sheen; Chia-Yo Ou; Te-Yao Hsu; Kuender D Yang
Journal:  Cell Mol Immunol       Date:  2011-02-14       Impact factor: 11.530

Review 5.  Modulating toll-like receptor 7 and 9 responses as therapy for allergy and autoimmunity.

Authors:  Damir Matesic; Aleksander Lenert; Petar Lenert
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.806

6.  Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding.

Authors:  Robert F Ashman; J Adam Goeken; Eicke Latz; Petar Lenert
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

7.  Endosomal Toll-Like Receptors Mediate Enhancement of Interleukin-17A Production Triggered by Epstein-Barr Virus DNA in Mice.

Authors:  Marwa Shehab; Nour Sherri; Hadi Hussein; Noor Salloum; Elias A Rahal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 8.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

9.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.